Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.22
ZTS's Cash-to-Debt is ranked lower than
79% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. ZTS: 0.22 )
Ranked among companies with meaningful Cash-to-Debt only.
ZTS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.16 Max: 4.34
Current: 0.22
0.09
4.34
Equity-to-Asset 0.20
ZTS's Equity-to-Asset is ranked lower than
91% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ZTS: 0.20 )
Ranked among companies with meaningful Equity-to-Asset only.
ZTS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.2 Max: 0.69
Current: 0.2
0.12
0.69
Debt-to-Equity 3.04
ZTS's Debt-to-Equity is ranked lower than
96% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. ZTS: 3.04 )
Ranked among companies with meaningful Debt-to-Equity only.
ZTS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 2.85 Max: 5.14
Current: 3.04
0.02
5.14
Debt-to-EBITDA 2.97
ZTS's Debt-to-EBITDA is ranked lower than
58% of the 495 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.92 vs. ZTS: 2.97 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ZTS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.08  Med: 2.64 Max: 5.61
Current: 2.97
0.08
5.61
Interest Coverage 9.92
ZTS's Interest Coverage is ranked lower than
70% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. ZTS: 9.92 )
Ranked among companies with meaningful Interest Coverage only.
ZTS' s Interest Coverage Range Over the Past 10 Years
Min: 7.26  Med: 8.42 Max: 26.77
Current: 9.92
7.26
26.77
Piotroski F-Score: 7
Altman Z-Score: 5.04
Beneish M-Score: -2.64
WACC vs ROIC
7.24%
23.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 34.15
ZTS's Operating Margin % is ranked higher than
95% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.97 vs. ZTS: 34.15 )
Ranked among companies with meaningful Operating Margin % only.
ZTS' s Operating Margin % Range Over the Past 10 Years
Min: 7.79  Med: 19.14 Max: 34.15
Current: 34.15
7.79
34.15
Net Margin % 20.35
ZTS's Net Margin % is ranked higher than
87% of the 802 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.32 vs. ZTS: 20.35 )
Ranked among companies with meaningful Net Margin % only.
ZTS' s Net Margin % Range Over the Past 10 Years
Min: -3.62  Med: 10.06 Max: 20.35
Current: 20.35
-3.62
20.35
ROE % 59.35
ZTS's ROE % is ranked higher than
98% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. ZTS: 59.35 )
Ranked among companies with meaningful ROE % only.
ZTS' s ROE % Range Over the Past 10 Years
Min: 6.58  Med: 24.4 Max: 64.27
Current: 59.35
6.58
64.27
ROA % 12.76
ZTS's ROA % is ranked higher than
87% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. ZTS: 12.76 )
Ranked among companies with meaningful ROA % only.
ZTS' s ROA % Range Over the Past 10 Years
Min: 4.16  Med: 7.57 Max: 12.76
Current: 12.76
4.16
12.76
ROC (Joel Greenblatt) % 60.14
ZTS's ROC (Joel Greenblatt) % is ranked higher than
91% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. ZTS: 60.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ZTS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.99  Med: 28.73 Max: 60.14
Current: 60.14
16.99
60.14
3-Year Revenue Growth Rate 4.10
ZTS's 3-Year Revenue Growth Rate is ranked lower than
55% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ZTS: 4.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ZTS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 2.5  Med: 4.05 Max: 16.3
Current: 4.1
2.5
16.3
3-Year EBITDA Growth Rate 20.10
ZTS's 3-Year EBITDA Growth Rate is ranked higher than
73% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. ZTS: 20.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ZTS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -2.8  Med: 20.75 Max: 677.8
Current: 20.1
-2.8
677.8
3-Year EPS without NRI Growth Rate 14.70
ZTS's 3-Year EPS without NRI Growth Rate is ranked higher than
61% of the 663 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. ZTS: 14.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ZTS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.4 Max: 45.1
Current: 14.7
0
45.1
GuruFocus has detected 3 Warning Signs with Zoetis Inc ZTS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ZTS's 30-Y Financials

Financials (Next Earnings Date: 2019-02-16 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

ZTS Guru Trades in Q4 2017

Joel Greenblatt 5,612 sh (+40.72%)
Frank Sands 128,389 sh (+435.87%)
MS Global Franchise Fund 576,481 sh (+0.28%)
George Soros Sold Out
Robert Olstein Sold Out
Paul Tudor Jones Sold Out
Caxton Associates Sold Out
Steven Cohen 100,038 sh (-86.12%)
Jim Simons 275,100 sh (-69.52%)
Pioneer Investments 659,352 sh (-44.17%)
Mario Gabelli 468,402 sh (-8.29%)
Eaton Vance Worldwide Health Sciences Fund 476,558 sh (-4.51%)
» More
Q1 2018

ZTS Guru Trades in Q1 2018

Lee Ainslie 18,920 sh (New)
Paul Tudor Jones 5,323 sh (New)
Mairs and Power 4,140 sh (New)
Joel Greenblatt 368,279 sh (+6462.35%)
Jim Simons 350,900 sh (+27.55%)
Pioneer Investments 2,768,388 sh (+319.86%)
Frank Sands 172,460 sh (+34.33%)
Steven Cohen Sold Out
Mario Gabelli 393,645 sh (-15.96%)
Eaton Vance Worldwide Health Sciences Fund 323,897 sh (-32.03%)
MS Global Franchise Fund 551,036 sh (-4.41%)
» More
Q2 2018

ZTS Guru Trades in Q2 2018

Steven Cohen 18,000 sh (New)
Joel Greenblatt 409,857 sh (+11.29%)
Lee Ainslie 118,600 sh (+526.85%)
Paul Tudor Jones 19,531 sh (+266.92%)
Pioneer Investments 4,666,581 sh (+68.57%)
Frank Sands 179,135 sh (+3.87%)
Jim Simons 672,800 sh (+91.74%)
Mairs and Power 4,140 sh (unchged)
Mario Gabelli 276,770 sh (-29.69%)
Eaton Vance Worldwide Health Sciences Fund 247,786 sh (-23.50%)
MS Global Franchise Fund 504,511 sh (-8.44%)
» More
Q3 2018

ZTS Guru Trades in Q3 2018

Jana Partners 32,000 sh (New)
Caxton Associates 8,111 sh (New)
Jim Simons 2,062,100 sh (+206.50%)
Frank Sands 239,935 sh (+33.94%)
Pioneer Investments 4,723,490 sh (+1.22%)
Paul Tudor Jones 47,396 sh (+142.67%)
MS Global Franchise Fund 535,381 sh (+6.12%)
Eaton Vance Worldwide Health Sciences Fund 247,786 sh (unchged)
Mairs and Power 4,140 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 263,042 sh (-4.96%)
Lee Ainslie 97,010 sh (-18.20%)
Joel Greenblatt 135,671 sh (-66.90%)
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:TSE:4502, XTER:MRK, SHSE:600276, NYSE:AGN, NAS:MYL, NSE:SUNPHARMA, TSE:4523, NYSE:TEVA, SHSE:600518, SHSE:600196, SZSE:000538, TSE:4507, XPAR:IPN, TSE:4508, NYSE:PRGO, OCSE:LUN, SZSE:000963, JSE:APN, XSWX:VIFN, HKSE:03320 » details
Traded in other countries:ZOE.Germany, ZTS.Mexico,
Headquarter Location:USA
Zoetis Inc is a developer and manufacturer of drugs providing medicines for animal health, and vaccines for livestock and companion animals. Its products are anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Zoetis Inc sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns the majority of its revenue from production animals (cattle, pigs, poultry, and so on) but also sells companion animal (dogs, horses, cats) products. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Guru Investment Theses on Zoetis Inc

KEELEY All Cap Value Fund Comments on Zoetis - Apr 23, 2018

Zoetis (NYSE:ZTS) is an animal health company that was a spinoff from Pfizer. The company reported very strong quarterly earnings and issued solid 2018 guidance that was higher than Wall Street estimates. Zoetis remains well positioned to continue to increase share in the livestock and companion animal markets while being insulated from the drug pricing and healthcare reform issues pressuring the human pharmaceutical companies.



From Keeley All Cap Value Fund 1st quarter 2018 shareholder letter.



Check out Keeley Asset Management Corp latest stock trades

Keeley Funds Comments on Zoetis - Aug 14, 2017

Zoetis (NYSE:ZTS) is an animal health company that was a spin off from Pfizer. The company reported very strong quarterly earnings and raised guidance for the full year. Early in the quarter, the company announced the acquisition of Nextvet, which strengthens their pipeline by adding an injectable pain platform to further diversify their animal health portfolio. Zoetis remains well positioned to continue to increase share in the livestock and companion animal markets while being insulated from the drug pricing and healthcare reform issues pressuring the human pharmaceutical companies.



From Keeley All Cap Value Fund second quarter 2017 shareholder commentary.



Check out Keeley Asset Management Corp latest stock trades

Keeley Funds Comments on Zoetis - Aug 14, 2017

Zoetis (NYSE:ZTS) is an animal health company that was a spin off from Pfizer. The company reported very strong quarterly earnings and raised guidance for the full year. Early in the quarter, the company announced the acquisition of Nextvet, which strengthens their pipeline by adding an injectable pain platform to further diversify their animal health portfolio. Zoetis remains well positioned to continue to increase share in the livestock and companion animal markets while being insulated from the drug pricing and healthcare reform issues pressuring the human pharmaceutical companies.



From Keeley All Cap Value Fund second quarter 2017 shareholder commentary.



Check out Keeley Asset Management Corp latest stock trades

Bill Ackman Comments on Zoetis - May 08, 2017

On November 9, 2016, we sold our last shares of Zoetis (NYSE:ZTS), about two years after we publicly announced an 8.5% ownership stake. Despite the high quality nature of the business and its strong management team, we sold to redeploy the capital in certain new investments.

We purchased our stake in Zoetis at an average cost of approximately $37 per share. Shortly thereafter, we met with the Zoetis management to discuss our views on potential initiatives to create shareholder value. On February 4, 2015, Zoetis agreed to add then-Pershing Square investment team member (and healthcare industry veteran) Bill Doyle and Actavis Executive Chairman Paul Bisaro to the board on April 13, 2015.

Over the course of our ownership, ZTS developed and implemented a number of value-enhancing initiatives including restructuring its supply chain, pursuing organic revenue growth opportunities while reducing costs, and setting a goal of increasing operating margins from ~25% in 2014 to ~34% by 2017. Zoetis outperformed each of these objectives during our ownership.

During our more than two-year ownership, Zoetis generated a total shareholder return, including dividends, of 57.9%.

From 2016 annual letter to shareholders of Pershing Square by Bill Ackman (Trades, Portfolio).

Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis - Mar 30, 2017



On November 9, 2016, we sold our last shares of Zoetis (NYSE:ZTS), about two years after we publicly announced an 8.5% ownership stake. Despite the high quality nature of the business and its strong management team, we sold to redeploy the capital in certain new investments.

We purchased our stake in Zoetis at an average cost of approximately $37 per share. Shortly thereafter, we met with the Zoetis management to discuss our views on potential initiatives to create shareholder value. On February 4, 2015, Zoetis agreed to add then-Pershing Square investment team member (and healthcare industry veteran) Bill Doyle and Actavis Executive Chairman Paul Bisaro to the board on April 13, 2015.

Over the course of our ownership, ZTS developed and implemented a number of value-enhancing initiatives including restructuring its supply chain, pursuing organic revenue growth opportunities while reducing costs, and setting a goal of increasing operating margins from ~25% in 2014 to ~34% by 2017. Zoetis outperformed each of these objectives during our ownership.

During our more than two-year ownership, Zoetis generated a total shareholder return, including dividends, of 57.9%.

From Bill Ackman (Trades, Portfolio)'s Pershing Square 2016 annual report.


Check out Bill Ackman latest stock trades

Top Ranked Articles about Zoetis Inc

New Research Coverage Highlights Zoetis, TripAdvisor, The Gap, Unit, WestRock, and Verastem — Consolidated Revenues, Company Growth, and Expectations for 2018
KEELEY All Cap Value Fund Comments on Zoetis Guru stock highlight
Zoetis (NYSE:ZTS) is an animal health company that was a spinoff from Pfizer. The company reported very strong quarterly earnings and issued solid 2018 guidance that was higher than Wall Street estimates. Zoetis remains well positioned to continue to increase share in the livestock and companion animal markets while being insulated from the drug pricing and healthcare reform issues pressuring the human pharmaceutical companies. Read more...

Ratios

vs
industry
vs
history
PE Ratio 38.21
ZTS's PE Ratio is ranked lower than
74% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.77 vs. ZTS: 38.21 )
Ranked among companies with meaningful PE Ratio only.
ZTS' s PE Ratio Range Over the Past 10 Years
Min: 27.31  Med: 38.63 Max: 133.08
Current: 38.21
27.31
133.08
Forward PE Ratio 25.91
ZTS's Forward PE Ratio is ranked lower than
77% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.60 vs. ZTS: 25.91 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 38.21
ZTS's PE Ratio without NRI is ranked lower than
73% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.20 vs. ZTS: 38.21 )
Ranked among companies with meaningful PE Ratio without NRI only.
ZTS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 27.31  Med: 38.63 Max: 133.08
Current: 38.21
27.31
133.08
Price-to-Owner-Earnings 28.65
ZTS's Price-to-Owner-Earnings is ranked higher than
50% of the 324 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.95 vs. ZTS: 28.65 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ZTS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 27.76  Med: 57.81 Max: 271.57
Current: 28.65
27.76
271.57
PB Ratio 20.66
ZTS's PB Ratio is ranked lower than
98% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. ZTS: 20.66 )
Ranked among companies with meaningful PB Ratio only.
ZTS' s PB Ratio Range Over the Past 10 Years
Min: 12.62  Med: 18.21 Max: 24.4
Current: 20.66
12.62
24.4
PS Ratio 7.79
ZTS's PS Ratio is ranked lower than
78% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ZTS: 7.79 )
Ranked among companies with meaningful PS Ratio only.
ZTS' s PS Ratio Range Over the Past 10 Years
Min: 3.11  Med: 4.91 Max: 8.13
Current: 7.79
3.11
8.13
Price-to-Free-Cash-Flow 29.02
ZTS's Price-to-Free-Cash-Flow is ranked lower than
51% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.84 vs. ZTS: 29.02 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ZTS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 25.69  Med: 46.71 Max: 90.56
Current: 29.02
25.69
90.56
Price-to-Operating-Cash-Flow 24.49
ZTS's Price-to-Operating-Cash-Flow is ranked lower than
60% of the 392 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.00 vs. ZTS: 24.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ZTS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.62  Med: 32.47 Max: 41.95
Current: 24.49
21.62
41.95
EV-to-EBIT 25.67
ZTS's EV-to-EBIT is ranked lower than
68% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. ZTS: 25.67 )
Ranked among companies with meaningful EV-to-EBIT only.
ZTS' s EV-to-EBIT Range Over the Past 10 Years
Min: 20.2  Med: 25 Max: 41.6
Current: 25.67
20.2
41.6
EV-to-EBITDA 22.48
ZTS's EV-to-EBITDA is ranked lower than
71% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. ZTS: 22.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZTS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.5  Med: 20.9 Max: 32.1
Current: 22.48
16.5
32.1
EV-to-Revenue 8.54
ZTS's EV-to-Revenue is ranked lower than
76% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.24 vs. ZTS: 8.54 )
Ranked among companies with meaningful EV-to-Revenue only.
ZTS' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.8  Med: 5.7 Max: 9
Current: 8.54
3.8
9
PEG Ratio 2.56
ZTS's PEG Ratio is ranked lower than
62% of the 317 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. ZTS: 2.56 )
Ranked among companies with meaningful PEG Ratio only.
ZTS' s PEG Ratio Range Over the Past 10 Years
Min: 1.88  Med: 2.72 Max: 3.29
Current: 2.56
1.88
3.29
Current Ratio 4.06
ZTS's Current Ratio is ranked higher than
73% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. ZTS: 4.06 )
Ranked among companies with meaningful Current Ratio only.
ZTS' s Current Ratio Range Over the Past 10 Years
Min: 1.96  Med: 2.84 Max: 4.38
Current: 4.06
1.96
4.38
Quick Ratio 2.63
ZTS's Quick Ratio is ranked higher than
66% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. ZTS: 2.63 )
Ranked among companies with meaningful Quick Ratio only.
ZTS' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.61 Max: 2.92
Current: 2.63
1.07
2.92
Days Inventory 288.92
ZTS's Days Inventory is ranked lower than
91% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.80 vs. ZTS: 288.92 )
Ranked among companies with meaningful Days Inventory only.
ZTS' s Days Inventory Range Over the Past 10 Years
Min: 125.75  Med: 284.81 Max: 325.24
Current: 288.92
125.75
325.24
Days Sales Outstanding 59.27
ZTS's Days Sales Outstanding is ranked higher than
66% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 81.76 vs. ZTS: 59.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZTS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.27  Med: 74.93 Max: 91.07
Current: 59.27
59.27
91.07
Days Payable 47.63
ZTS's Days Payable is ranked lower than
74% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.32 vs. ZTS: 47.63 )
Ranked among companies with meaningful Days Payable only.
ZTS' s Days Payable Range Over the Past 10 Years
Min: 47.28  Med: 59.8 Max: 110.66
Current: 47.63
47.28
110.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.56
ZTS's Dividend Yield % is ranked lower than
86% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. ZTS: 0.56 )
Ranked among companies with meaningful Dividend Yield % only.
ZTS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.21  Med: 0.66 Max: 1.08
Current: 0.56
0.21
1.08
Dividend Payout Ratio 0.20
ZTS's Dividend Payout Ratio is ranked higher than
78% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. ZTS: 0.20 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ZTS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.19  Med: 0.24 Max: 0.49
Current: 0.2
0.19
0.49
3-Year Dividend Growth Rate 13.40
ZTS's 3-Year Dividend Growth Rate is ranked higher than
66% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. ZTS: 13.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ZTS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.9
Current: 13.4
0
24.9
Forward Dividend Yield % 0.72
ZTS's Forward Dividend Yield % is ranked lower than
86% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.66 vs. ZTS: 0.72 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.56
ZTS's 5-Year Yield-on-Cost % is ranked lower than
86% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. ZTS: 0.56 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ZTS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.21  Med: 0.66 Max: 1.08
Current: 0.56
0.21
1.08
3-Year Average Share Buyback Ratio 1.00
ZTS's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.30 vs. ZTS: 1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZTS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1  Med: 0.1 Max: 1
Current: 1
-0.1
1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.89
ZTS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
80% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. ZTS: 3.89 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ZTS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 3.88  Med: 4.5 Max: 5.27
Current: 3.89
3.88
5.27
Price-to-Median-PS-Value 1.58
ZTS's Price-to-Median-PS-Value is ranked lower than
82% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.94 vs. ZTS: 1.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ZTS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.65  Med: 1 Max: 1.59
Current: 1.58
0.65
1.59
Price-to-Peter-Lynch-Fair-Value 1.94
ZTS's Price-to-Peter-Lynch-Fair-Value is ranked lower than
71% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.41 vs. ZTS: 1.94 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ZTS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.93  Med: 2.69 Max: 3.15
Current: 1.94
1.93
3.15
Earnings Yield (Greenblatt) % 3.89
ZTS's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. ZTS: 3.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ZTS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.4  Med: 4 Max: 5
Current: 3.89
2.4
5
Forward Rate of Return (Yacktman) % 21.31
ZTS's Forward Rate of Return (Yacktman) % is ranked higher than
76% of the 421 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.96 vs. ZTS: 21.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ZTS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 12.8  Med: 15.9 Max: 21.4
Current: 21.31
12.8
21.4

More Statistics

Revenue (TTM) (Mil) $5,721.00
EPS (TTM) $ 2.38
Beta0.82
Volatility8.89%
52-Week Range $70.20 - 96.57
Shares Outstanding (Mil)480.45

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 5,790 6,278 6,715 7,072
EBIT (Mil $) 2,025 2,259 2,570
EBITDA (Mil $) 2,263 2,524 2,766 3,025
EPS ($) 3.01 3.39 3.88 4.45
EPS without NRI ($) 3.01 3.39 3.88 4.45
EPS Growth Rate
(Future 3Y To 5Y Estimate)
14.00%
Dividends per Share ($) 0.44 0.46 0.42

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}